JP2024083460A5 - - Google Patents

Download PDF

Info

Publication number
JP2024083460A5
JP2024083460A5 JP2024060790A JP2024060790A JP2024083460A5 JP 2024083460 A5 JP2024083460 A5 JP 2024083460A5 JP 2024060790 A JP2024060790 A JP 2024060790A JP 2024060790 A JP2024060790 A JP 2024060790A JP 2024083460 A5 JP2024083460 A5 JP 2024083460A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
tablet
weight
microcrystalline cellulose
high grade
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024060790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024083460A (ja
JP7860163B2 (ja
Filing date
Publication date
Priority claimed from JP2021507989A external-priority patent/JP7469293B2/ja
Application filed filed Critical
Publication of JP2024083460A publication Critical patent/JP2024083460A/ja
Publication of JP2024083460A5 publication Critical patent/JP2024083460A5/ja
Priority to JP2026076282A priority Critical patent/JP2026110857A/ja
Application granted granted Critical
Publication of JP7860163B2 publication Critical patent/JP7860163B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024060790A 2018-08-17 2024-04-04 Ag10の製剤 Active JP7860163B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026076282A JP2026110857A (ja) 2018-08-17 2026-04-30 Ag10の製剤

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862765154P 2018-08-17 2018-08-17
US62/765,154 2018-08-17
JP2021507989A JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤
PCT/US2019/046789 WO2020037189A1 (en) 2018-08-17 2019-08-16 Formulations of ag10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021507989A Division JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026076282A Division JP2026110857A (ja) 2018-08-17 2026-04-30 Ag10の製剤

Publications (3)

Publication Number Publication Date
JP2024083460A JP2024083460A (ja) 2024-06-21
JP2024083460A5 true JP2024083460A5 (cg-RX-API-DMAC7.html) 2024-11-28
JP7860163B2 JP7860163B2 (ja) 2026-05-15

Family

ID=69524257

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021507989A Active JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤
JP2024060790A Active JP7860163B2 (ja) 2018-08-17 2024-04-04 Ag10の製剤
JP2026076282A Pending JP2026110857A (ja) 2018-08-17 2026-04-30 Ag10の製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2021507989A Active JP7469293B2 (ja) 2018-08-17 2019-08-16 Ag10の製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026076282A Pending JP2026110857A (ja) 2018-08-17 2026-04-30 Ag10の製剤

Country Status (27)

Country Link
US (4) US11260047B2 (cg-RX-API-DMAC7.html)
EP (2) EP4647068A3 (cg-RX-API-DMAC7.html)
JP (3) JP7469293B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210046708A (cg-RX-API-DMAC7.html)
CN (2) CN112804998A (cg-RX-API-DMAC7.html)
AU (2) AU2019321583C1 (cg-RX-API-DMAC7.html)
BR (1) BR112020026493A2 (cg-RX-API-DMAC7.html)
CA (1) CA3104695A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000289A1 (cg-RX-API-DMAC7.html)
DK (1) DK3836920T3 (cg-RX-API-DMAC7.html)
EA (1) EA202190561A1 (cg-RX-API-DMAC7.html)
ES (1) ES3055121T3 (cg-RX-API-DMAC7.html)
FI (1) FI3836920T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20251603T1 (cg-RX-API-DMAC7.html)
IL (2) IL325404A (cg-RX-API-DMAC7.html)
LT (1) LT3836920T (cg-RX-API-DMAC7.html)
MA (1) MA53238A (cg-RX-API-DMAC7.html)
MX (1) MX2021001761A (cg-RX-API-DMAC7.html)
PL (1) PL3836920T3 (cg-RX-API-DMAC7.html)
PT (1) PT3836920T (cg-RX-API-DMAC7.html)
RS (1) RS67572B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101393PA (cg-RX-API-DMAC7.html)
SI (1) SI3836920T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500463T1 (cg-RX-API-DMAC7.html)
TW (1) TWI834708B (cg-RX-API-DMAC7.html)
UA (1) UA128256C2 (cg-RX-API-DMAC7.html)
WO (1) WO2020037189A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
WO2023052652A1 (en) 2021-10-01 2023-04-06 Sandoz Ag Crystalline form of acoramidis hydrochloride
WO2025235883A1 (en) 2024-05-10 2025-11-13 Eidos Therapeutics, Inc. Acoramidis for use in the treatment of renal dysfunction

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4255329A (en) 1973-10-02 1981-03-10 Syva Company Double receptor fluorescent immunoassay
US4117149A (en) 1975-09-12 1978-09-26 Pfizer Inc. 4-oxo-4h-benzopyrans as animal growth promotants
US4261928A (en) 1977-08-05 1981-04-14 Sterling Drug Inc. 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4171365A (en) 1977-08-05 1979-10-16 Sterling Drug Inc. Antiviral aryloxyalkylpyrazoles
US4234725A (en) 1979-10-24 1980-11-18 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4232161A (en) 1979-10-24 1980-11-04 Sterling Drug Inc. 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-(2-pyridinyl)-1H-pyrazole
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4668640A (en) 1981-12-11 1987-05-26 Abbott Laboratories Fluorescence polarization immunoassay utilizing substituted carboxyfluoresceins
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
GB2120242A (en) 1982-04-30 1983-11-30 Erba Farmitalia Ergoline derivatives
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4764521A (en) 1983-07-18 1988-08-16 Eli Lilly And Company Leukotriene antagonists and a method of use there as
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
US5315015A (en) 1992-11-10 1994-05-24 Hoffmann-La Roche Inc. Compounds having improved fluorescence in fluorescence polarization immunoassays and immunoassays utilizing same
TW260612B (cg-RX-API-DMAC7.html) 1993-01-05 1995-10-21 Asahi Chemical Ind
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
HU224548B1 (hu) 1993-04-07 2005-10-28 Taiho Pharmaceutical Co. Ltd. Tiazolidinszármazékok és ezeket tartalmazó gyógyszerkészítmények, valamint eljárás előállításukra
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5744368A (en) 1993-11-04 1998-04-28 Research Foundation Of State University Of New York Methods for the detection of soluble amyloid β-protein (βAP) or soluble transthyretin (TTR)
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
IL150524A0 (en) 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
JP2005513026A (ja) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド 高コレステロール血症、異脂肪血症および他の代謝障害;癌、および他の疾患を治療するn−置換複素環
PT1511710E (pt) 2002-05-31 2014-02-26 Proteotech Inc Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
TW200403061A (en) 2002-06-04 2004-03-01 Glaxo Group Ltd Pharmaceutical compositions
WO2004096808A1 (en) 2003-04-28 2004-11-11 De Novo Pharmaceuticals Limited Triazine compounds and their use
US20050113394A1 (en) 2003-11-26 2005-05-26 Wood Allen W. Pharmaceutical compositions
WO2005118166A2 (en) 2004-06-04 2005-12-15 Teva Pharmaceutical Industries, Ltd. Pharmaceutical composition containing irbesartan
US8026366B2 (en) 2004-06-18 2011-09-27 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
WO2006088694A1 (en) 2005-02-14 2006-08-24 Wyeth SUBSTITUTED THIENYL AND FURYL ACYLGUANIDINES AS β-SECRETASE MODULATORS
US20070000505A1 (en) 2005-02-24 2007-01-04 Philip Morris Usa Inc. Smoking article with tobacco beads
WO2007012019A2 (en) 2005-07-18 2007-01-25 Horizon Therapeutics, Inc. Medicaments containing famotidine and ibuprofen and administration of same
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
SG173409A1 (en) 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
EA200900821A1 (ru) 2006-12-22 2010-02-26 Новартис Аг Производные 1-аминометил-l-фенилциклогексана как ингибиторы дпп-iv (дипептидилпептидазы-iv)
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
BRPI0811446A2 (pt) 2007-05-11 2014-10-29 Lilly Co Eli " 2-[4-(pirazol-4-ilalquil)piperazin-1-il]-3-fenil pirazinas e piridinas e 3-[4-(pirazol-4-ilalquil)piperazin-1-il]-2-fenil piridinas como antagonistas de receptor 5-ht7"
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2(mglu2 수용체)의 포지티브 조절자로서의 헤테로사이클릭 화합물
ES2351274T3 (es) 2007-06-06 2011-02-02 Torrent Pharmaceuticals Ltd Nuevos compuestos.
CN101790526A (zh) 2007-06-08 2010-07-28 雅培制药有限公司 用作激酶抑制剂的5-杂芳基取代的吲唑化合物
WO2009048557A1 (en) 2007-10-10 2009-04-16 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
CN101868228B (zh) 2007-11-21 2016-12-07 大日本住友制药株式会社 口腔内崩解片
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
FR2926722B1 (fr) 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
EA019033B1 (ru) 2008-03-26 2013-12-30 Новартис Аг Ингибиторы дезацетилазы в, основанные на гидроксамате
JO3041B1 (ar) 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US8048887B2 (en) 2008-09-11 2011-11-01 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7994171B2 (en) 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
TR201805216T4 (en) 2008-10-28 2018-06-21 Arena Pharm Inc COMPOSITIONS OF A USEFUL 5-HT2A SEROTONINE RECEPTOR MODULATOR FOR THE TREATMENT OF RELATED DISORDERS
AR074199A1 (es) 2008-11-20 2010-12-29 Glaxosmithkline Llc Compuesto de 6-(4-pirimidinil)-1h-indazol, composiciones farmaceuticas que lo comprenden y su uso para preparar un medicamento util para el tratamiento o disminucion de la gravedad del cancer.
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
AR079022A1 (es) 2009-11-02 2011-12-21 Sanofi Aventis Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion
CA3002948C (en) 2009-11-13 2020-10-27 Astrazeneca Uk Limited Immediate release tablet formulations
US20110144211A1 (en) 2009-12-11 2011-06-16 Lars Hermann Use of microcrystalline cellulose for interfering with the extraction of ephedrine
ES2900353T3 (es) 2010-04-07 2022-03-16 Vertex Pharma Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
EP2566333A4 (en) 2010-05-07 2014-04-02 Univ Leland Stanford Junior IDENTIFICATION OF STABILIZERS OF MULTIMEDER PROTEINS
JP5759457B2 (ja) 2010-06-29 2015-08-05 旭化成ケミカルズ株式会社 セルロースと無機化合物を含む複合粒子
CA2822039C (en) 2010-12-16 2019-05-28 Allergan, Inc. Sulfur derivatives as chemokine receptor modulators
CN103841962B (zh) 2011-07-07 2016-08-17 爱尔兰詹森科学公司 地瑞纳韦配制品
CA2848493A1 (en) 2011-09-14 2013-03-21 Celgene Corporation Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amide
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
WO2014118809A1 (en) 2013-01-29 2014-08-07 Actavis Group Ptc Ehf. Pharmaceutical composition with linezolid
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
US20160045609A1 (en) 2014-08-14 2016-02-18 Mamoun M. Alhamadsheh Conjugation of pharmaceutically active agents with transthyretin ligands through adjustable linkers to increase serum half-life
MX376083B (es) 2015-06-04 2025-03-07 Pfizer Formas de dosificacion solidas de palbociclib.
EP4233846B1 (en) 2015-06-30 2024-12-04 Gilead Sciences, Inc. Pharmaceutical formulations
MX375424B (es) 2015-07-31 2025-03-06 Pfizer Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
TW202332423A (zh) * 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
EP3582773A4 (en) 2017-02-17 2021-03-10 Eidos Therapeutics, Inc. PROCESS FOR THE MANUFACTURING OF AG-10, ITS INTERMEDIATES AND SALTS THEREOF
WO2019046167A1 (en) 2017-08-30 2019-03-07 Acadia Pharmaceuticals Inc. PIMAVANSERIN FORMULATIONS
WO2019183463A1 (en) 2018-03-23 2019-09-26 Eidos Therapeutics, Inc. Methods of treating ttr amyloidosis using ag10
LT3836920T (lt) 2018-08-17 2026-01-26 Eidos Therapeutics, Inc. Ag10 farmacinės formos
AU2021266739B2 (en) 2020-05-06 2024-11-28 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
AU2021378320A1 (en) 2020-11-11 2023-06-22 Spero Therapeutics, Inc. High dosage tebipenem pivoxil tablet formulation
US20230330006A1 (en) 2020-12-18 2023-10-19 Amneal Complex Products Rearch LLC Sustained Release Compositions Comprising Liothyronine
JP2026508526A (ja) 2023-03-01 2026-03-11 エイドス セラピューティクス,インコーポレイティド アコラミディスの投与を受けているttrアミロイドーシス患者における強力なトランスサイレチン(ttr)安定化

Similar Documents

Publication Publication Date Title
NO320844B1 (no) Celecoxibpreparat, fremgangsmate for fremstilling av dette og av farmasoytisk preparat som omfatter det og anvendelse av celeboxibpreparatet for fremstilling av preparat og medikament.
JP7537032B2 (ja) ラサギリン又はその医薬用塩の舌下フィルム剤及びその製造方法、使用
CN103974695A (zh) 苦味被遮蔽的枸橼酸西地那非口服薄膜制剂
TWI658841B (zh) 包含苯并咪唑衍生物的新穎調配物
FR2802424A1 (fr) Comprime matriciel permettant la liberation prolongee de trimetazidine apres administration par voie orale
EP0942718B1 (fr) Comprime de maleate de trimebutine pellicule
US20110105613A1 (en) Moisture resistant container systems for rapidly bioavailable dosage forms
JP2024522817A (ja) フェニルピロールアミノグアニジン塩及び製剤
CN111328280A (zh) 制备和使用内昔芬的方法
TW202021583A (zh) Ag10之調配物
JP6335269B2 (ja) 医薬ソフトゼラチンカプセル剤形
JP6335270B2 (ja) 変性グアーガムを用いる医薬ソフトゼラチンカプセル剤形
JP4185974B2 (ja) カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
JP2018118966A5 (cg-RX-API-DMAC7.html)
JP6758488B2 (ja) カンデサルタンおよびアムロジピンを含む単一層からなる複合製剤
JP2023548348A (ja) 固体製剤
JP2022537685A5 (cg-RX-API-DMAC7.html)
CN107224430A (zh) 一种含盐酸雷莫司琼的药物组合物
WO2013119607A2 (en) Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
JP7355846B2 (ja) 固形製剤
JP2017530137A (ja) アムロジピン及びロサルタンを含む固形医薬組成物
JP2025517683A5 (cg-RX-API-DMAC7.html)
CN108553439B (zh) 一种含s-羧甲基-l-半胱氨酸的肠溶片剂
JP2019504866A (ja) 新規組成物
CN108338978B (zh) 一种s-羧甲基-l-半胱氨酸肠溶微丸胶囊